JPWO2021127394A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021127394A5 JPWO2021127394A5 JP2022537420A JP2022537420A JPWO2021127394A5 JP WO2021127394 A5 JPWO2021127394 A5 JP WO2021127394A5 JP 2022537420 A JP2022537420 A JP 2022537420A JP 2022537420 A JP2022537420 A JP 2022537420A JP WO2021127394 A5 JPWO2021127394 A5 JP WO2021127394A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- suppository
- mrna
- gelatin
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 29
- 239000000829 suppository Substances 0.000 claims 22
- 108020004999 messenger RNA Proteins 0.000 claims 16
- 108010010803 Gelatin Proteins 0.000 claims 14
- 229920000159 gelatin Polymers 0.000 claims 14
- 239000008273 gelatin Substances 0.000 claims 14
- 235000019322 gelatine Nutrition 0.000 claims 14
- 235000011852 gelatine desserts Nutrition 0.000 claims 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 10
- 150000002632 lipids Chemical class 0.000 claims 8
- 239000003623 enhancer Substances 0.000 claims 7
- 230000035699 permeability Effects 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 claims 2
- QUDMPGCGJQLFPF-UHFFFAOYSA-N 2-dodecanoyloxyethyl(trimethyl)azanium Chemical compound CCCCCCCCCCCC(=O)OCC[N+](C)(C)C QUDMPGCGJQLFPF-UHFFFAOYSA-N 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 241000219161 Theobroma Species 0.000 claims 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims 2
- 239000003833 bile salt Substances 0.000 claims 2
- 229940093761 bile salts Drugs 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940110456 cocoa butter Drugs 0.000 claims 2
- 235000019868 cocoa butter Nutrition 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims 2
- 235000019197 fats Nutrition 0.000 claims 2
- 125000005456 glyceride group Chemical group 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 150000003873 salicylate salts Chemical class 0.000 claims 2
- 229940045845 sodium myristate Drugs 0.000 claims 2
- JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 claims 2
- 229950006451 sorbitan laurate Drugs 0.000 claims 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 241000792859 Enema Species 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951844P | 2019-12-20 | 2019-12-20 | |
| US62/951,844 | 2019-12-20 | ||
| PCT/US2020/065945 WO2021127394A2 (fr) | 2019-12-20 | 2020-12-18 | Administration par voie rectale d'arn messager |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508882A JP2023508882A (ja) | 2023-03-06 |
| JPWO2021127394A5 true JPWO2021127394A5 (fr) | 2023-12-25 |
Family
ID=74554205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537420A Pending JP2023508882A (ja) | 2019-12-20 | 2020-12-18 | メッセンジャーｒｎａの直腸送達 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230051811A1 (fr) |
| EP (1) | EP4076393A2 (fr) |
| JP (1) | JP2023508882A (fr) |
| KR (1) | KR20220142432A (fr) |
| CN (1) | CN115515559A (fr) |
| AU (1) | AU2020408059A1 (fr) |
| BR (1) | BR112022012085A2 (fr) |
| CA (1) | CA3162368A1 (fr) |
| CO (1) | CO2022010079A2 (fr) |
| IL (1) | IL294073A (fr) |
| MX (1) | MX2022007756A (fr) |
| WO (1) | WO2021127394A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022336209A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| WO2023073228A1 (fr) | 2021-10-29 | 2023-05-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
| WO2023144330A1 (fr) | 2022-01-28 | 2023-08-03 | CureVac SE | Inhibiteurs de facteurs de transcription codés par un acide nucleique |
| WO2023227608A1 (fr) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli |
| WO2024089638A1 (fr) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Vaccin à base d'acide nucléique |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| DD273980B5 (de) * | 1988-07-12 | 1994-04-14 | Berlin Chemie Ag | Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| CA2569664C (fr) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Arn interferant encapsule dans des lipides |
| EP4332227A1 (fr) | 2005-08-23 | 2024-03-06 | The Trustees of the University of Pennsylvania | Arn contenant des nucléosides modifiées et leurs procédés d'utilisation |
| ES2475065T3 (es) | 2008-10-09 | 2014-07-10 | Tekmira Pharmaceuticals Corporation | Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos |
| CN104910025B (zh) | 2008-11-07 | 2019-07-16 | 麻省理工学院 | 氨基醇类脂质和其用途 |
| TR201811076T4 (tr) | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
| WO2011012316A2 (fr) | 2009-07-31 | 2011-02-03 | Ludwig-Maximilians-Universität | Arn ayant une combinaison de nucléotides non modifiés et modifiés pour l'expression protéique |
| NZ600616A (en) | 2009-12-01 | 2014-11-28 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| DK2718269T3 (en) | 2011-06-08 | 2018-04-09 | Translate Bio Inc | SPLITLY LIPIDS |
| KR102272498B1 (ko) | 2011-10-27 | 2021-07-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체 |
| EP3620447B1 (fr) | 2012-03-29 | 2021-02-17 | Translate Bio, Inc. | Lipides cationiques ionisables |
| AU2014236396A1 (en) | 2013-03-14 | 2015-08-13 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger RNA |
| BR112015022505A2 (pt) | 2013-03-14 | 2017-10-24 | Shire Human Genetic Therapies | avaliação quantitativa para eficiência do cap de rna mensageiro |
| EA201690576A1 (ru) * | 2013-10-22 | 2016-10-31 | Шир Хьюман Дженетик Терапис, Инк. | Липидные композиции для доставки матричной рнк |
| EP3872066A1 (fr) | 2013-12-19 | 2021-09-01 | Novartis AG | Lipides et compositions lipidiques pour l'administration d'agents actifs |
| JP6571679B2 (ja) | 2014-04-25 | 2019-09-04 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| EP3587409B8 (fr) | 2014-05-30 | 2022-07-13 | Translate Bio, Inc. | Lipides biodégradables pour l'administration d'acides nucléiques |
| ES2834556T3 (es) | 2014-06-25 | 2021-06-17 | Acuitas Therapeutics Inc | Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos |
| EP3164379A1 (fr) | 2014-07-02 | 2017-05-10 | Massachusetts Institute of Technology | Lipidoïdes dérivés de polyamine-acide gras et leurs utilisations |
| JP6782171B2 (ja) | 2014-07-02 | 2020-11-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａのカプセル化 |
| EP3247363A4 (fr) | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Compositions de nanoparticules lipidiques |
| US20180085474A1 (en) | 2015-01-23 | 2018-03-29 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| AU2016278970B2 (en) | 2015-06-19 | 2020-10-29 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| JP7072386B2 (ja) | 2015-06-29 | 2022-05-20 | アクイタス セラピューティクス インコーポレイテッド | 核酸の送達のための脂質および脂質ナノ粒子製剤 |
| US20190119357A1 (en) * | 2015-07-23 | 2019-04-25 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| WO2017117528A1 (fr) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipides et formulations de nanoparticules de lipides pour la libération d'acides nucléiques |
| JP7245651B2 (ja) | 2016-03-30 | 2023-03-24 | インテリア セラピューティクス，インコーポレイテッド | Ｃｒｉｓｐｒ／ｃａｓ構成成分のための脂質ナノ粒子製剤 |
| EP3538073A1 (fr) | 2016-11-10 | 2019-09-18 | Translate Bio, Inc. | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm |
| EP3538136A1 (fr) * | 2016-11-10 | 2019-09-18 | Translate Bio, Inc. | Administration sous-cutanée d'arn messager |
| IL266501B2 (en) | 2016-11-10 | 2024-06-01 | Translate Bio Inc | An improved ICE-based lipid nanoparticle formulation for delivery of mRNA |
| AU2018224325B2 (en) | 2017-02-27 | 2024-05-02 | Translate Bio, Inc. | Large scale synthesis of messenger RNA |
| US10808241B2 (en) | 2017-02-27 | 2020-10-20 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| AU2018224318B2 (en) | 2017-02-27 | 2024-06-20 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
-
2020
- 2020-12-18 IL IL294073A patent/IL294073A/en unknown
- 2020-12-18 WO PCT/US2020/065945 patent/WO2021127394A2/fr active Application Filing
- 2020-12-18 AU AU2020408059A patent/AU2020408059A1/en active Pending
- 2020-12-18 KR KR1020227025025A patent/KR20220142432A/ko unknown
- 2020-12-18 EP EP20851262.4A patent/EP4076393A2/fr active Pending
- 2020-12-18 BR BR112022012085A patent/BR112022012085A2/pt unknown
- 2020-12-18 CN CN202080096344.0A patent/CN115515559A/zh active Pending
- 2020-12-18 MX MX2022007756A patent/MX2022007756A/es unknown
- 2020-12-18 CA CA3162368A patent/CA3162368A1/fr active Pending
- 2020-12-18 JP JP2022537420A patent/JP2023508882A/ja active Pending
- 2020-12-18 US US17/786,971 patent/US20230051811A1/en active Pending
-
2022
- 2022-07-18 CO CONC2022/0010079A patent/CO2022010079A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2509076C2 (ru) | Пролекарства нестероидных противовоспалительных средств (nsaia) c очень высокой скоростью проникновения через кожу и мембраны и новые медицинские применения указанных пролекарств | |
| JP2002522357A (ja) | 胆汁酸を有する清浄水溶液型製剤の調剤 | |
| JP2005530743A5 (fr) | ||
| Nishida et al. | Role of gastric mucosal constitutive and inducible nitric oxide synthases in the development of stress-induced gastric mucosal lesions in rats | |
| JPWO2021127394A5 (fr) | ||
| WO2006080903A3 (fr) | Preparations autoemulsifiantes a concentration elevee a base de coenzyme q10 a usage nutritionnel | |
| Edwards et al. | Enteritis and colitis associated with mefenamic acid | |
| ES2761636T3 (es) | Composiciones y métodos para suministro de agentes terapéuticos en el colon | |
| Hong et al. | The use of colon in the surgical treatment of benign stricture of the esophagus | |
| WO2001005406A1 (fr) | Preparations de glycyrrhizine pour absorption par voie transmuqueuse | |
| RU2430733C2 (ru) | Фармацевтическая композиция для лечения заболеваний предстательной железы (варианты) | |
| Begg | Persistent priapism due to secondary carcinoma in the corpora cavernosa | |
| EP1251844B1 (fr) | Preparation laxative contenant de la l-arginine | |
| JP2002512195A (ja) | Ｎ−アセチルグルコサミンの結腸投与による炎症性腸疾患用の組成物およびその治療 | |
| JPS6355489B2 (fr) | ||
| JP2002537248A (ja) | 発泡性緩下薬 | |
| WO2021216494A1 (fr) | Compositions et procédés pour le traitement d'un saignement gastro-intestinal | |
| Kishino et al. | Colonic Dieulafoy lesion successfully treated by endoclips: a rare cause of lower gastrointestinal bleeding | |
| CN110200909A (zh) | 基于alfa-亚麻酸修饰的单甲氧基聚乙二醇-聚乙烯亚胺的两性霉素B胶束及其制备 | |
| Fábián et al. | Watermelon‐stomach as a cause of chronic iron deficiency anemia in a patient with systemic sclerosis | |
| JP2001518498A (ja) | 空洞器官内腫瘍の全体的診断および／または治療用局所医薬製造のためのδ−アミノレブリン酸の利用 | |
| Shaffer et al. | The biliary system | |
| SUGIMURA et al. | Portal‐systemic shunting in a patient with normal portal vein pressures and histological evidence of idiopathic portal hypertension | |
| Marzouk et al. | Le diagnostic de hernie obturatrice étranglée est-il encore clinique? | |
| Shehzad et al. | Small Intestinal Hemorrhage as a Rare Presentation of Metastatic Testicular Choriocarcinoma: 2027 |